Full Breakdown
India’s First Approved Dengue Vaccine Set for Private-Market Launch in 2027
By Drooid · · How we work
Distribution Deal Marks Core Event
On September 18, 2026, Takeda Pharmaceutical Company and Dr Reddy’s Laboratories announced an exclusive agreement for Dr Reddy’s to promote and distribute Takeda’s dengue vaccine Qdenga in India’s private market for paediatric and adult vaccination. The vaccine is expected to become available in the first half of 2027, pending local registration, import-licence and quality-release processes.
Background & Context
Dengue, transmitted by Aedes mosquitoes, remains a major public-health challenge in India. A nationwide surveillance study by the Indian Council of Medical Research found all four dengue virus serotypes co-circulate and that 1 in 14 patients are concurrently infected with multiple serotypes. Reported dengue cases have risen 11-fold over two decades, representing roughly one-third of the global burden.
The Central Drugs Standard Control Organisation (CDSCO) granted marketing authorisation to Qdenga in July 2026 for individuals aged 4 to 60 years, making it India’s first dengue vaccine cleared by the regulator.
Data & Statistics
- Efficacy: 2025 analysis reported 61.2 % efficacy against virologically confirmed dengue and 84.1 % against dengue-related hospitalisation at 4.5 years. Later data show 80.2 % efficacy against confirmed dengue one year after the second dose and 90.4 % against hospitalisation after 18 months.
- Doses: Two 0.5 ml sub-cutaneous injections three months apart.
- Global reach: Approved in 43 countries since 2022, with over 32 million doses distributed worldwide; WHO-prequalified and recommended for use without pre-vaccination screening in high-endemic settings.
- Manufacturing capacity: Takeda aims for 100 million doses per year by 2030, combining output from its German plant and a partnership with Bio E in India.
Official Statements & Responses
Both parties emphasized that pricing has not yet been fixed and that the marketing authorisation is only the first step toward commercial availability.
Verbatim Quotes
- “As the second-largest vaccine player in India, we believe the introduction of India’s first approved dengue vaccine is an important development for the country’s healthcare landscape.” — Dr Reddy’s Laboratories
- “Receiving marketing authorization is just the first step,” — Mahender Nayak
- “More from World More from World Dr Mahender Nayak, Head of Intercontinental Markets, International Business Unit, Takeda, noted, ”In parallel, our private-market collaboration with Dr Reddy’s will help enable timely private-market access for eligible individuals once QDENGA becomes available in India.” — Mahender Nayak
Conflicting Reports & Gaps
- Announcement timing: Some outlets treat the September 18 2026 announcement as a future event, while others report it as already occurred.
- Pricing: No definitive price has been disclosed; companies say pricing will be set after regulatory steps are complete.
- Public-sector rollout: Inclusion in the Universal Immunisation Programme is mentioned as a long-term goal, but no timeline or pricing for government procurement has been provided.
What’s Next
- Completion of the Registration Certificate and Import Licence with Indian authorities.
- Finalisation of quality-release procedures before commercial distribution.
- Negotiation of a price structure that balances affordability with manufacturing costs.
- Ongoing engagement with the Parliamentary Committee on Health to explore inclusion of Qdenga in the public immunisation programme.
- Scale-up of production through Takeda’s partnership with Bio E, targeting 100 million doses annually by 2030.
The partnership positions Qdenga as the first vaccine to augment India’s dengue-prevention toolkit, complementing existing vector-control and surveillance measures while awaiting full market entry in early 2027.